| Segment Reporting Disclosure [Text Block] |
10. SEGMENT INFORMATION
We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) Cancer Diagnostics, (ii) Cancer Therapeutics and (iii) our legacy patent licensing activities. The following represents selected financial information for our segments for the nine and three months ended July 31, 2019 and 2018 and as of July 31, 2019 and October 31, 2018:
| For the Nine Months Ended July 31,
|
|
| 2019
| | 2018
|
| Net loss:
| | | | | |
| Cancer Diagnostics
| $
| (4,024,785)
| | $
| (3,783,854)
|
| Cancer Therapeutics
| | (4,807,668)
| | | (4,583,070)
|
| Patent licensing
|
| (875,138)
| |
| (484,640)
|
| Total
| $
| (9,707,591)
| | $
| (8,851,564)
|
| | | | | |
| Operating costs and expenses excluding non-cash share based compensation expense:
| | | | | |
| Cancer Diagnostics
| $
| 1,953,760
| | $
| 1,692,865
|
| Cancer Therapeutics
| | 2,084,694
| | | 1,807,515
|
| Patent licensing
|
| 1,070,408
| |
| 1,266,448
|
| Total
| $
| 5,108,862
| | $
| 4,766,828
|
| | | | | |
| Operating costs and expenses excluding non-cash share based compensation expense
| $
| 5,108,862
| | $
| 4,766,828
|
| Plus non-cash share-based compensation expense
|
| 4,902,512
| |
| 5,227,016
|
| Total operating costs and expenses
| $
| 10,011,374
| | $
| 9,993,844
|
| | | | | |
| For the Three Months Ended July 31,
|
| 2019
| | 2018
|
| Net loss:
| | | | | |
| Cancer Diagnostics
| $
| (917,363)
| | $
| (2,359,568)
|
| Cancer Therapeutics
| | (1,203,468)
| | | (2,901,708)
|
| Patent licensing
|
| (45,217)
| |
| (332,300)
|
| Total
| $
| (2,166,048)
| | $
| (5,593,576)
|
| |
| | |
|
| Operating costs and expenses excluding non-cash share based compensation expense:
| | | | | |
| Cancer Diagnostics
| $
| 507,356
| | $
| 569,512
|
| Cancer Therapeutics
| | 801,704
| | | 359,006
|
| Patent licensing
|
| 44,454
| |
| 411,453
|
| Total
| $
| 1,353,514
| | $
| 1,339,971
|
| | | | | |
| Operating costs and expenses excluding non-cash share based compensation expense
| $
| 1,353,514
| | $
| 1,339,971
|
| Plus non-cash share-based compensation expense
|
| 830,898
| |
| 4,628,333
|
| Total operating costs and expenses
| $
| 2,184,412
| | $
| 5,968,304
|
| | | | | |
| July 31, 2019
| | October 31, 2018
|
| |
| Total assets:
| | | | | |
| Cancer Diagnostics
| $
| 3,201,233
| | $
| 2,545,803
|
| Cancer Therapeutics
| | 3,279,496
| | | 2,157,359
|
| Patent licensing
|
| 361,977
| |
| 1,745,380
|
| Total
| $
| 6,842,706
| | $
| 6,448,542
|
Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.
|